EC OKs Pfizer/Merck bladder cancer med

 

• BAVENCIO maintenance treatment significantly extended median overall survival versus standard of care in the Phase III JAVELIN Bladder 100 study
• First and only immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III trial
• BAVENCIO first-line maintenance therapy is recommended for use by the ESMO Bladder Cancer Guidelines

https://www.biospace.com/article/releases/european-commission-approves-bavencio-avelumab-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma/